+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Tumor Necrosis Factor Inhibitors Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024

  • PDF Icon


  • 300 Pages
  • March 2018
  • Region: Global
  • Kuick Research
  • ID: 4471056

“Global Tumor Necrosis Factor Inhibitors Drug Market Dosage Price & Clinical Pipeline Outlook 2024” Report Highlights:

  • Global TNF Inhibitors Market Trends
  • Key TNF Inhibitors Drug Sales, Price & Dosage Analysis
  • Global TNF Inhibitors Clinical Pipeline by Company, Indication & Phase
  • Sales Projections of Key Drugs Till 2024
  • Clinical Pipeline Data by Phase
  • TNF Inhibitors Market Future Outlook
  • Marketed Drug Clinical & Patent Insight

Tumor Necrosis Factor (TNF) is a vital protein that plays a key role in the regulation of immune cells. Several Clinical studies have proved that the level of TNF is significantly high in patients suffering from Autoimmune Diseases like Rheumatoid arthritis, Ankylosing Spondylitis and Crohn’s Disease. Each of these indications have shown high prevalence globally in the past few years with million of new incidence being reported every year.

This discovery has lead pharmaceutical companies to develop therapeutics which aims at inhibiting the overexpression of TNF. TNF inhibitors, also known as Anti TNF therapeutics work by attaching to TNF receptors, thus lowering the levels of TNF in the body; resulting in prevention of inflammatory response and chronic pain. The use of TNF inhibitors in each of the above mentioned clinical conditions have been found to provide excellent therapeutic efficacy with minimal side effects, thus making them global leaders in the autoimmune disorder, pain management and inflammatory therapeutic segment.

Etanercept (Enbrel), Infliximab (Remicade), Adalimumab (Humira) , Certolizumab, and Golimumab (Simponi) are the key therapeutics that make up the global TNF inhibitors Market. Among these, Humira and Remicade have made it to the list of Blockbuster drugs of 2017 with global sales of US$ 17.6 Billion and US$ 5.9 Billion Respectively. Remicade is closely followed by another TNF inhibitor Enbrel, with global sales of US$ 5.8 Billion.

With the launch of biosimilar version of each TNF inhibitors, the global TNF inhibitors market is bound to undergo a dynamic change with respect to revenues.
Factors like patent expiration, involvement of emerging biotechnology and pharmaceutical firms, collaboration and support from regulatory authorities for easy approval has facilitated the commercialization of novel TNF inhibitors and their biosimilars.

Although the TNF inhibitors market is being flooded with wide range of TNF Biosimilars; certain therapeutics are bound to remain dominant in the global TNF inhibitors market. For instance, Despite Humira being one of the earliest therapeutic in the market, it has managed to acquire the largest market size globally. The success of Humira indicates high market potential in the newly approved therapeutics that are anticipated to enter the market soon, thus proving that the TNF inhibitor segment is here to stay.

While North America is still the Dominant market when it comes to TNF inhibitors; Analysis shows the market dominance shifting towards European and Asian regions during the forecast period. Patent Expiry of Existing TNF inhibitors, Favorable reimbursement plans, lenient drug regulation laws are few key reasons for the shift of the TNF inhibitors market towards the European and Asia Pacific Region. Further, launching of new products, advancement in scientific and technical aspect of Drug development and increasing investment in healthcare are fuelling factors that provide an optimistic forecast in the developing Asian regions like China and India.

Global Increase in elderly population and rise in the prevalence of rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease are key factors that drive the TNF inhibitors market. Studies indicate that 20% of the global population is suffering from some kind of chronic pain, with rheumatoid arthritis showing the highest prevalence. Estimated data indicates that the number of people suffering from Rheumatoid arthritis alone might rise to over 78 Million by 2040, thus ensuring exponential growth to the TNF inhibitors Market.

Table of Contents

1. Tumor Necrosis Factor - An Overview
1.1 Prologue to Tumor Necrosis Factor
1.2 History & Discovery of Tumor Necrosis Factors
2. Significance of Tumor Necrosis Factor
2.1 TNF in Cell Signaling & Immunity
2.1.1 Tumor Necrosis Factor Receptor 1
2.1.2 Tumor Necrosis Factor Receptor 2
2.2 Role of TNF in Cancer
2.3 Disease Related to TNF & Members of Its Family
3. Working Mechanism of Tumor Necrosis Factors (TNF) Inhibitors & Their Therapeutic Evolution
3.1 Tumor Necrosis Factor & Immune Response
3.2 Tumor Necrosis Factor Inhibition by Monoclonal Antibodies
4. Approaches Used in Development of TNF Inhibitors
4.1 Monoclonal Antibody Approach
4.2 Recombinant DNA Technology Approach
5. Global Tumor Necrosis Factor Alpha Inhibitors Pipeline Overview
6. Global Tumor Necrosis Factor Alpha Inhibitors Clinical Pipeline by Company, Indication & Phase
6.1 Unknown
6.2 Research
6.3 Preclinical
6.4 Clinical
6.5 Phase-I
6.6 Phase-I/II
6.7 Phase-II
6.8 Phase-II/III
6.9 Phase-III
6.10 Preregistration
6.11 Registered
7. Marketed Global Tumor Necrosis Factor Alpha Inhibitors Clinical Insight by Company & Indication
7.1 Golimumab (Shinponi, Simponi, Simponi Aria, Simponi I.V, Sympony & Symposony)
7.2 Pomalidomide (Imnovid & Pomalyst)
7.3 Adalimumab (Humira & Raheara)
7.4 Infliximab (Remicade)
7.5 Certolizumab Pegol (CIMZIA AutoClicks Prefilled Pen, Cimzia & Simziya)
7.6 Apremilast (Otezla)
7.7 Infliximab Biosimilar - Celltrion
7.8 Lumbricus Rubellus Extract (Inflectra & Remsima)
7.9 Adalimumab Biosimilar (AdaliRel & Adfrar)
7.10 Infliximab Biosimilar (Infimab)
7.11 Infliximab Biosimilar - Bionovis/ The Instituto Vital Brazil
7.12 Adalimumab Biosimilar (Exemptia)
7.13 Anti-Tumour Necrosis Factor-Alpha Antibody Oral
8. Price, Dosage & Treatment Cost Analysis of Commercially Available TNF Based Therapeutics
8.1 Cimzia (Certolizumab Pegol)
8.2 Enbrel (Etanercept)
8.2.1 Benepali - Etanercept Biosimilar
8.3 Humira ( Adalimumab)
8.3.1 Amjevita - Humira Biosimilar
8.3.2 Cyltezo - Second Biosimilar to Humira
8.4 Otezla (Apremilast)
8.5 Remicade (Infliximab)
8.5.1 Remsima - Infliximab Biosimilar
8.5.2 Inflectra - Infliximab Biosimilar
8.6 Simponi (Golimumab)
9. Current Market Trends & Recent Advances in the TNF Inhibitors Segment
9.1 Dominance of TNF Inhibitors in Global Therapeutics Market
9.2 Global TNF Inhibitor Market by Indication - Market Size & Growing Opportunity
9.2.1 Rheumatoid Arthritis
9.2.2 Psoriasis and psoriatic arthritis (PsA)
9.2.3 Crohn’s Disease
9.2.4 Ankylosing Spondylitis
9.3 Global TNF Inhibitors Market by Region
9.3.1 US
9.3.2 Europe
9.3.3 Asia- Pacific
9.3.4 Middle East & Africa (MEA)
10. TNF Inhibitor- Sales & Patent Analysis
10.1 TNF Inhibitor Market by Sales
10.1.1 Cimzia
10.1.2 Enbrel
10.1.3 Humira
10.1.4 Remicade
10.2 TNF Inhibitor Market by Approvals & Patent
10.3 TNF Inhibitor Biosimilar Sales Analysis
11. TNF Inhibitors Market Driving Parameters12. Restraining Factors of the Global TNF Inhibitors Market
13. Global - TNF Inhibitors Future Forecast & Sales Projections
13.1 Impact of Biosimilar ‘Benepali’ on Enbrel Sales
13.2 Affordable Alternatives to Humira & Their Effect on Global Humira Sales
13.3 Remicade & Its Biosimilar
13.4 Conclusion & Executive Summary
14. Competitive Landscape
14.1 AbbVie
14.2 Ablynx
14.3 Apogenix
14.4 AryoGen Biopharma
14.5 Bionovis
14.6 CASI Pharmaceuticals
14.7 Celltrion
14.8 Celgene Corporation
14.9 Delenex Therapeutics
14.10 Dexa Medica
14.11 EPIRUS Biopharmaceuticals
14.12 Janssen Biotech
14.13 GlaxoSmithKline
14.14 HanAll Biopharma
14.15 Intas Pharmaceuticals
14.16 LEO Pharma
14.17 LG Life Sciences
14.18 MedImmune
14.19 Momenta Pharmaceuticals
14.20 Novartis
14.22 Reliance Life Sciences
14.23 Sandoz
14.24 Samsung Bioepis
14.25 Sanofi-Aventis
14.26 Shanghai CP Guojian Pharmaceutical
14.27 Shanghai Pharmaceuticals
14.28 Simcere Pharmaceutical
14.29 Toyama Chemical
14.30 Tsumura
14.31 UCB
14.32 Zydus Cadila
List of Figures:
Figure 1-1: Multiple Roles of TNF
Figure 1-2: Historical timeline of Tumor Necrosis Factor
Figure 1-3: Historical Timeline of Tumor Necrosis Factor Inhibitors
Figure 2-1: TNF Factor Types & Their Inhibition
Figure 2-2: Diseases Related to TNF & Its Family Members
Figure 3-1: General Working Mechanism of TNF Inhibitors
Figure 5-1: Global Tumor Necrosis Factor Alpha Inhibitors Pipeline by Phase (%), 2018 till 2024
Figure 5-2: Global Tumor Necrosis Factor Alpha Inhibitors Pipeline by Phase (Number), 2018 till 2024
Figure 5-3: Global Tumor Necrosis Factor Alpha Inhibitors Pipeline by Phase (%), 2018 till 2024
Figure 5-4: Global Tumor Necrosis Factor Alpha Inhibitors Pipeline by Phase (Number), 2018 till 2024
Figure 8-1: Cimzia - Dose for Crohn's Disease (mg/week)
Figure 8-2: Cimzia - Dose for Rheumatoid Arthritis (US$)
Figure 8-3: Cimzia - Dose for Psoriatic Arthritis (mg)
Figure 8-4: Cimzia - Dose for Ankolysing Spondylitis (mg)
Figure 8-5: Cimzia (Certolizumab Pegol) - Average Price (US$)
Figure 8-6: Cimzia - Treatment Cost Analysis, 2018
Figure 8-7: TNF inhibition by Enbrel, Working Mechanism
Figure 8-8: Enbrel - Dosage Forms & Strength (mg & ml)
Figure 8-9: Enbrel - Dosage & Frequency for Arthritis, AS & PsA (mg/Week)
Figure 8-10: Enbrel - Dose for Juvenile Idiopathic Arthritis (mg & mg/kg)
Figure 8-11: Enbrel - Subcutaneous Kit Price (US$/Unit), 2018
Figure 8-12: Enbrel - Prefilled Syringe Price (US$/Vial), 2018
Figure 8-13: Global - Enbrel Price by Region (US$)
Figure 8-14: Enbrel - Treatment Cost Analysis (US$/Month)
Figure 8-15: Enbrel - Price per QALY Gained (US$), 2018
Figure 8-16: Humira - Mechanism of Action
Figure 8-17: Humira - Dosage Analysis by Indication (mg)
Figure 8-18: Humira - Dosage Analysis for Crohn's Disease (mg)
Figure 8-19: Humira - Dose for Plaque Psoriasis (mg)
Figure 8-20: Humira - Subcutaneous Kit Price (US$), 2017
Figure 8-21: Humira - Average Treatment Cost Analysis per Month (US$), 2017
Figure 8-22: Otezla - Dose for Plaque Psoriasis
Figure 8-23: Otezla - Price Analysis (US$/Unit), 2017
Figure 8-24: Remicade (Infliximab)- Mode of Action
Figure 8-25: Remicade - Dose for Crohn's Disease (mg/kg)
Figure 8-26: Remicade - Dose for Rheumatoid Arthritis (mg/kg)
Figure 8-27: Remicade- Price Analysis for 100mg Vial (US$), 2018
Figure 8-28: Simponi - Availability by Concentration (mg/0.5ml)
Figure 8-29: Simponi - Dosage Analysis (mg)
Figure 8-30: Simponi - Price Analysis (US$/ml), 2018
Figure 9-1: Global- Therapeutics Market Segmentation by size (%)
Figure 9-2: Global - Rheumatoid Arthritis Prevalence (per 100,000 Individuals), 2016-2017
Figure 9-3: Global - Psoriasis & Psoriatic Arthritis Prevalence, 2015-2016
Figure 9-4: Global- Crohn's Disease Epidemiology (per 100,000 Individuals), 2012-2017
Figure 9-5: Global - Ankylosing Spondylitis (per 100,000 Individuals), 2018
Figure 9-6: US - TNF inhibitors Market by Prevalence of Indication (per 1000 Individuals) , 2017
Figure 9-7: Humira Cost Analysis by Region- US v/s India (US$/Vial), 2017
Figure 10-1: Global- Cimzia Sales (US$ Million), 2016 & 2017
Figure 10-2: Global - Enbrel Sales (US$ Million), 2014-2017
Figure 10-3: Global- Humira Sales (US$ Million), 2014-2017
Figure 10-4: Global- Remicade Sales (US$ Million), 2014-2017
Figure 10-5: Global - TNF Inhibitors Patent by Number
Figure 10-6: Patent Analysis - Patent Expiration by Year
Figure 10-7: Global - TNF Inhibitor Biosimilar Sales (US$ Million), 2015-2017
Figure 10-8: Global - Benepali Sales (US$ Million), 2016-2017
Figure 11-1: Driving Factors of the TNF Inhibitors Segment
Figure 12-1: Challenging Factors of the TNF Inhibitors Market
Figure 13-1: Global - Enbrel Sales Future Forecast (US$ Million), 2017-2024
Figure 13-2: Global - Humira Sales Forecast (US$ Million), 2017-2024
Figure 13-3: Global - Amjevita Sales Future Forecast (US$ Million), 2020 & 2024
Figure 13-4: Global - Remicade Future Sales Forecast (US$ Million), 2016-2024
Figure 13-5: Global - Blockbuster TNF Inhibitors Sales (US$ Billion), 2017
Figure 14-1: Ablynx - Clinical Pipeline
Figure 14-2: Apogenix - Clinical Pipeline
Figure 14-3: Casi Pharmaceutical - Clinical Pipeline
Figure 14-4: Celgene - Clinical Pipeline
Figure 14-5: EPIRUS Biopharmaceuticals - Clinical Pipeline
Figure 14-6: HanAll Biopharma - Clinical Pipeline
Figure 14-7: Novartis - Clinical Pipeline
Figure 14-8: Sandoz - Clinical Pipeline
Figure 14-9: Toyama Chemical - Clinical Pipeline
Figure 14-10: Zydus Cadila - Clinical Pipeline



Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie
  • Ablynx
  • Apogenix
  • AryoGen Biopharma
  • Bionovis
  • CASI Pharmaceuticals
  • Celgene Corporation
  • Celltrion
  • Delenex Therapeutics
  • Dexa Medica
  • EPIRUS Biopharmaceuticals
  • GlaxoSmithKline
  • HanAll Biopharma
  • Intas Pharmaceuticals
  • Janssen Biotech
  • LEO Pharma
  • LG Life Sciences
  • MedImmune
  • Momenta Pharmaceuticals
  • Novartis
  • Reliance Life Sciences
  • Samsung Bioepis
  • Sandoz
  • Sanofi-Aventis
  • Shanghai CP Guojian Pharmaceutical
  • Shanghai Pharmaceuticals
  • Simcere Pharmaceutical
  • Toyama Chemical
  • Tsumura
  • UCB
  • Zydus Cadila